Faslodex Seen to Ably Treat Advanced and Hormone Receptor-Positive Breast Cancers

Faslodex Seen to Ably Treat Advanced and Hormone Receptor-Positive Breast Cancers
Women with locally advanced or metastatic hormone receptor-positive breast cancer may strongly benefit from treatment with the estrogen receptor degrader Faslodex (fulvestrant), according to the results of a Phase 3 study. The findings, recently presented at the European Society for Medical oncology (ESMO) Congress, held Oct. 7–11 in Denmark, reveal that Faslodex improves progression-free survival compared to Arimidex (anastrozole), particularly in patients with less aggressive disease. The growth of certain types of breast cancer, called hormone receptor-positive cancers, is promoted by the female hormones estrogen and progesterone. In addition to chemotherapy, drugs that inhibit the effects of these hormones are commonly used to treat these cancers. Unlike aromatase inhibitors such as Arimidex, which decrease the estrogen levels by preventing its production, Faslodex works by binding to estrogen receptors in breast cancer cells, which decreases estrogen binding. The randomized, double-blind, and multicenter Phase 3 FALCON trial (NCT01602380) was designed to assess the efficacy and tolerability of Faslodex compared to Arimidex in postmenopausal women with ER-positive, HER-negative locally advanced or metastatic breast cancer. The patients had not received any prior hormone therapy. The study enrolled 462 participants, who were randomized to receive either 500 mg intramuscular Faslodex on days 0, 14, and 28, and then every 28 days, or 1 mg Arimidex daily. Patients were allowed one line of chemotherapy. Afte
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.